EP0778834A1 - Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren - Google Patents
Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitorenInfo
- Publication number
- EP0778834A1 EP0778834A1 EP95928912A EP95928912A EP0778834A1 EP 0778834 A1 EP0778834 A1 EP 0778834A1 EP 95928912 A EP95928912 A EP 95928912A EP 95928912 A EP95928912 A EP 95928912A EP 0778834 A1 EP0778834 A1 EP 0778834A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- phenyl
- hydrogen
- 3alkyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- This invention relates to methods of treating cyclooxygenase mediated diseases and certain pharmaceutical compositions therefor.
- Non-steroidal, antiinflammatory drugs exert most of their antiinflammatory, analgesic and antipyretic activity and inhibit hormone-induced uterine contractions and certain types of cancer growth through inhibition of prostaglandin G/H synthase, also known as cyclooxygenase.
- prostaglandin G/H synthase also known as cyclooxygenase.
- cyclooxygenase- 1 the constitutive enzyme, as originally identified in bovine seminal vesicles.
- the gene for a second inducible form of cyclooxygenase (cyclooxygenase-2) has been cloned, sequenced and characterized initially from chicken, murine and human sources.
- This enzyme is distinct from the cyclooxygenase- 1 which has been cloned, sequenced and characterized from various sources including the sheep, the mouse and man.
- the second form of cyclooxygenase, cyclooxygenase-2 is rapidly and readily inducible by a number of agents including mitogens, endotoxin, hormones, cytokines and growth factors.
- prostaglandins have both physiological and pathological roles, we have concluded that the constitutive enzyme, cyclooxygenase- 1 , is responsible, in large part, for endogenous basal release of prostaglandins and hence is important in their physiological functions such as the maintenance of gastrointestinal integrity and renal blood flow.
- cyclooxygenase-2 is mainly responsible for the pathological effects of prostaglandins where rapid induction of the enzyme would occur in response to such agents as inflammatory agents, hormones, growth factors, and cytokines.
- a selective inhibitor of cyclooxygenase-2 will have similar antiinflammatory, antipyretic and analgesic properties to a conventional non-steroidal antiinflammatory drug, and in addition would inhibit hormone-induced uterine contractions and have potential anti-cancer effects, but will have a diminished ability to induce some of the mechanism-based side effects.
- such a compound should have a reduced potential for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced effect on bleeding times and possibly a lessened ability to induce asthma attacks in aspirin-sensitive asthmatic subjects.
- the invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I.
- the invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I. DETAILED DESCRIPTION OF THE INVENTION
- the invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I.
- A-B-C-D- is selected from the group consisting of:
- Rl is selected from the group consisting of
- R2 is selected from the group consisting of (a) Cl-6alkyl,
- heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one 1 letero atom which is S, O, or N, and optionally 1, 2, or 3 additional N atoms; or the heteroaryl is a monocyclic ring of 6 atoms, said ring having one hetero atom which is N, and optionally 1, 2, 3, or 4 additional N atoms; said substituents are selected from the group consisting of
- halo including fluoro, chloro, bromo and iodo
- R3 and R4 are the substituents residing on any position of
- NSAID non-steroidal anti-inflammatory drug
- PCC Pyridinium chlorochromate
- Ph phenyl
- PPA polyphosphoric acid r.t. r: room temperature
- Alkyl refers to linear or branched structures and combinations thereof.
- Halo includes F, Cl, Br, and I.
- Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers.
- the present invention is meant to comprehend such possible diastereomers as well as their racemic and resolved, enantiomerically pure forms and pharmaceutically acceptable salts thereof.
- Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.
- compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt, thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients.
- pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts.
- Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, such as arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like, and basic ion exchange resins.
- substituted amines including naturally occurring substituted
- the Compound of Formula I is useful for the relief of pain, fever and inflammation of a variety of conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns, injuries, following surgical and dental procedures.
- a compound may inhibit cellular neoplastic transformations and metastic tumor growth and hence can be used in the treatment of cancer.
- Compound I may also be of use in the treatment and/or prevention of cyclooxygenase-mediated proliferative disorders such as may occur in diabetic retinopathy and tumour angiogenesis.
- Compound I will also inhibit prostanoid-induced smooth muscle contraction by preventing the synthesis of contractile prostanoids and hence may be of use in the treatment of dysmenorrhea, premature labor, asthma, Alzheimer's Disease and osteoporosis.
- compound I By virtue of its high cyclooxygenase-2 (COX-2) activity and/or its specificity for cyclooxygenase-2 over cyclooxygenase- 1 (COX-1), compound I will prove useful as an alternative to conventional non-steroidal antiinflammatory drugs (NSAID'S) particularly where such non-steroidal antiinflammatory drugs may be contra-indicated such as in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; GI bleeding, coagulation disorders including anemia such as hypoprothrombinemia, haemophilia or other bleeding problems; kidney disease; those prior to surgery or taking anticoagulants.
- NSAID'S non-steroidal antiinflammatory drugs
- compositions for treating cyclooxygenase-2 mediated diseases as defined above comprising a non-toxic therapeutically effective amount of the compound of Formula I as defined above and one or more ingredients such as another pain reliever including acetominophen or phenacetin; a potentiator including caffeine; an H2-antagonist, aluminum or magnesium hydroxide, simethicone, a decongestant including phenylephrine, phenylpropanolamine, pseudoephedrine, oxymetazoline, epinephrine, naphazoline, xylometazoline, propylhexedrine, or levo- desoxyephedrine; an antiitussive including codeine, hydrocodone, caramiphen, carbetapentane, or
- the invention encompasses a method of treating cyclooxygenase mediated diseases comprising: administration to a patient in need of such treatment a non-toxic therapeutically effective amount of the compound of Formula I, optionally co-administered with one or more of such ingredients as listed immediately above.
- Compound I may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
- parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.
- the compound of the invention is effective in the treatment of humans.
- compositions for treating cyclooxygenase-2 mediated diseases as defined may optionally include one or more ingredients as listed above.
- compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
- Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- an oil medium for example peanut oil, liquid paraffin, or olive oil.
- Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethy- cellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene
- the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
- Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- a dispersing or wetting agent e.g., glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerin, glycerin, glycerin, glycerin, glycerin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol
- the pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions.
- the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
- Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
- the emulsions may also contain sweetening and flavouring agents.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
- the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally- acceptable diluent or solvent, for example as a solution in 1,3-butane diol.
- Suitable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- Compound I may also be administered in the form of a suppositories for rectal administration of the drug.
- These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- Such materials are cocoa butter and polyethylene glycols.
- creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula I are employed. (For purposes of this application, topical application shall include mouth washes and gargles.)
- 140 mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5 mg to about 7 g per patient per day.
- inflammation may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day.
- the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
- a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition.
- Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.
- the compounds of the present invention can be prepared according to the following methods. Method A
- Reaction of the readily available aldehyde XV with an organometallic reagent XVI provides allylic alcohol XVII, which can be oxidized to ketone XVIII by an oxidizing agent such as PDC, PCC, Mn ⁇ 2 or Swern's reagent.
- a peracid derivative can be used to convert XVIII to methyl sulphone XIX, which is converted to thiophene XX upon treatment with methyl thioglycolate and a base, such as a tertiary amine.
- Benzylic bromination of XX with NBS provides bromide XXI.
- Method D The difference between Method D and Method E is that the methylsulfonyl group is introduced at the end of the synthetic sequence in E.
- XXIV could be transformed to thiophene derivative XXVII. Oxidation of XXVII with peracid provides the desired compound XXIII.
- Table I and II illustrate compounds of Formula I, which are representative of the present invention.
- the compound of Formula I can be tested using the following assays to determine their cyclooxygenase-2 inhibiting and antiinflammatory activities.
- mice Male Sprague-Dawley rats (150-200 g) were fasted overnight and were given p.o. either vehicle (1% methocel) or a test compound. One hr later, a line was drawn using a permanent marker at the level above the ankle in one hind paw to define the area of the paw to be monitored. The paw volume (Vo) was measured using a plethysmometer (Ugo-Basile, Italy) based on the principle of water displacement. The animals were then injected subplantarly with 50 ⁇ l of 1 % carrageenan solution in saline (FMC Corp, Maine) into the paw using an insulin syringe with a 25-gauge needle (i.e.
- Compounds of the present invention are inhibitors of cyclooxygenase-2 and are thereby useful in the treatment of cyclooxygenase-2 mediated diseases as enumerated above.
- the activities of the compounds against cyclooxygenase may be seen in the representative results shown below.
- inhibition is determined by measuring the amount of prostaglandin E2 (PGE2) synthesized in the presence of arachidonic acid, cyclooxygenase- 1 or cyclooxygenase-2 and a putative inhibitor.
- PGE2 prostaglandin E2
- the IC50 values represent the concentration of putative inhibitor required to return PGE2 synthesis to 50% of that obtained as compared to the uninhibited control.
- a compound is a selective inhibitor of COX-2 over COX-1 if the ratio of IC50's for COX-1 : COX-2 is 100 or greater, preferably 500 or greater.
- melting points are uncorrected and d' indicates decomposition; the melting points given are those obtained for the materials prepared as described; polymorphism may result in isolation of materials with different melting points in some preparations;
- NMR data when given, NMR data is in the form of delta ( ⁇ ) values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS), determined at 300
- Step 1 2-phenoxy- 1 -(4-(methylthio)phenyl)ethanone
- Step 5 3-(4-(Methanesulfonyl)phenyl -2-phenylbenzorblfuran
- Step 1 2-phenylthio- 1 -(4-(methanesulfonyl)phenyl)ethanone To a solution of thiophenol (5.5 g) and 2-bromo-l-(4-
- Step 2 3-(4-(Methanesulfonyl)phenyl benzorblthiophene 2- ⁇ henylthio-l-(4-(methanesulfonyl)phenyl)ethanone (1 g) from Step 1 was mixed with PPA (10 g) and heated at 80°C for 30 minutes. The mixture was then cooled in an ice-water bath and ice was added. The aqueous was extracted twice with EtOAc. The organic layers were combined, washed with brine, dried over MgS ⁇ 4, filtered and the solvent evaporated in vacuo. Purification by silica gel chromatography using 30% EtOAc in hexane afforded 150 mg of the tide compound.
- Step 4 3-(4-(Methanesulfonyl)phenyl -2-phenylbenzorblthiophene
- Step 1 3-(4-(Methylthio)phenyl)-2-phenylinden- 1 -one
- Step 2 3-(4-(Methanesulfonyl)phenyl)-2-phenylinden- 1 -one
- Step 1 l-(4-Fluorophenyl)-2-(4-(methylthio)phenyl)ethanone
- Step 2 l-(4-Fluorophenyl)-2-(4-(methylsulfonyl)phenyl)ethanone
- Step 1 To a solution of l-(4-fluorophenyl)-2-(4-(methylthio)- phenyl ethanone from Example 4, Step 1 (2.50 g) in 1 ,2-dichloroethane (27.0 mL) were introduced the Vilsmeier reagent (Aldrich catalog,
- Step 2 cis,trans-4-Chloro-4-(4-fluorophenyl)-3-(4-(methylthio)- phenyl)-3-buten-2-ol
- Step 3 . cis,trans-4-Chloro-4-(4-fluorophenyl)-3-(4-(methylthio)- phenyl)-3-buten-2-one
- a solution of the product of Step 2 200 mg
- a solution of the product of Step 2 200 mg
- a solution of the product of Step 2 200 mg
- a solution of the product of Step 2 200 mg
- a solution of the product of Step 2 200 mg
- PDC 0.5 g of powered 4 A molecular sieve and 0.47 g of PDC.
- the mixture was stirred for 2 h, diluted with 15 mL of Et2 ⁇ , and then filtered through a pad of celite.
- the filtrate was concentrated in vacuo to give 180 mg of the crude title compound which was used for the next step without further purification.
- Step 4 cis,trans-4-Chloro-4-(4-fluorophenyl)-3-(4-(methyl- sulfonyl)phenyl)-3-buten-2-one
- the crude product of Step 3 (180 mg) was dissolved in 10 mL of 10: 1 CH2Cl2/MeOH and treated with 250 mg of MPPM. After stirring for 30 min, the reaction mixture was quenched with 20 mL of sat. NaHC03, and extracted with 50 ml of EtOAc. The extract was dried over Na2S04 and concentrated in vacuo to give 150 mg of the title compound.
- Step 5 3-Methyl-5-(4-fluorophenyl)-4-(4-(methylsulfonyl)- phenyl)thiophene-2-carboxylic acid methyl ester
- methyl thioglycolate 42 uL
- Step 6 3-Bromomethyl-5-(4-fluorophenyl)-4-(4-(methylsulfonyl)- phenyl)thiophene-2-carboxylic acid methyl ester
- Step 7 3-Hydroxymethyl-5-(4-fluorophenyl)-4-(4- (methylsulfonyl)phenyl)thiophene-2-carboxylic acid
- Step 8 2-(4-Fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-4H- thienor2.3-clfuran-6-one
- Example 6 Following the procedure of Example 6, but replacing l-(4- fluorophenyl)-2-(4-(methylthio)phenyl)ethanone by l-(3,4- difluorophenyl)-2-(4-(methylthio)phenyl)ethanone, the title compound was prepared.
- the starting ketone was prepared according to Example 4, step 1, beginning with 3,4-difluorobenzaldehyde.
- Step 1 3-Methyl-5-(4-fluorophenyl)-4-(4-(methylthiophenyl)- thiophene-2-carboxylic acid methyl ester
- Step 2 3-Bromomethyl-5-(4-fluorophenyl)-4-(4-(methylthio) phenyl)thiophene-2-carboxylic acid methyl ester
- Step 3 3-Hydroxymethyl-5-(4-fluorophenyl)-4-(4-(methylthio)- phenyl thiophene-2-carboxylic acid
- Step 5 2-(4-Fluorophenyl)-3-(4-(methylsulfinyl) ⁇ henyl)-4H- thieno 2,3-c]furan-6-one 2-(4-Fluorophenyl)-3-(4-(methylthio)phenyl)-4H-thieno-
- [2,3-c]furan-6-one (548 mg) (from Step 4) was dissolved in 10 mL of 10: 1 CH2Cl2/-MeOH and treated with 476 mg of MPPM at 0°C. After stirring for 15 min at 0°C and 1.5 h at room temperature, the reaction mixture was quenched with 20 mL of sat. NaHC03, and extracted with 50 ml of EtOAc. The extract was dried over MgS ⁇ 4 and concentrated in vacuo. The residue was purified by silica gel chromatography eluted with EtOAc to give 490 mg of the title compound.
- Step 6 2-(4-Fluorophenyl)-3-(4-(aminosulfonyl)phenyl)-4H- thienor2.3-c1furan-6-one
- Step 1 3-Cyanomethyl-4-(4-(methylthio)phenyl)-5-phenyl- thiophene-2-carboxylic acid methyl ester
- 3-bromomethyl-4-(4-(methylthio)phenyl)-5-phenyl- thiophene-2-carboxylic acid methyl ester ( 1 g, prepared by using the same procedure described for 3-bromomethyl-5-(fluorophenyl)-4-(4- (methylthio)phenyl)thiophene-2-carboxylic acid methyl ester of Example 8, Step 2 but substituting benzaldehyde for 4-fluorobenz- aldehyde) in DMSO (25 mL) in an ice bath was added powdered KCN.
- Step 2 [2-Hydroxymethyl-4-(4-(methylthio)phenyl)-5-phenylthio- phen-3-yllacetonitrile To a solution of 3-cyanomethyl-4-(4-(methylthio)phenyl)-
- Step 4 3-(4-(Methylthio)phenyl)-2-phenyl-4,7-dihydrothieno- l " 2.3-c1pyran-5-one
- Step 5 3-(4-(Methylsulfonyl)phenyl)-2-phenyl-4,7-dihydro- thienor2.3-clpyran-5-one
- a solution of 3-(4-(methylthio)phenyl)-2-phenyl-4,7- dihydrothieno[2,3-c]pyran-5-one (100 mg) and MPPM, (166 mg) in CH2CI2 (5 mL) and MeOH (1 mL) was stirred overnight.
- a solution of saturated NaHC ⁇ 3 was added to the reaction mixture which was extracted with EtOAc. The extract was washed with brine, dried over MgS04, filtered and the solvent was evaporated under vacuum.
- Step 1 l-(4-(methylthio)phenyl)-2-phenylethanone
- Step 2 2-(4-(Methylthio)phenyl)-3-phenyl-4H-thieno[2,3-c]furan- 6-one
- the title compound was prepared from l-(4-(methylthio)- phenyl)-2-phenylethanone by the procedures described in Steps 1, 2, 3,
- Step 3 2-(4-(Methylsulfonyl)phenyl)-3-phenyl-4H-thieno[2,3-c]- furan-6-one
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/297,461 US5521213A (en) | 1994-08-29 | 1994-08-29 | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US297461 | 1994-08-29 | ||
PCT/CA1995/000490 WO1996006840A1 (en) | 1994-08-29 | 1995-08-24 | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0778834A1 true EP0778834A1 (de) | 1997-06-18 |
EP0778834B1 EP0778834B1 (de) | 2000-01-26 |
Family
ID=23146414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95928912A Expired - Lifetime EP0778834B1 (de) | 1994-08-29 | 1995-08-24 | Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren |
Country Status (12)
Country | Link |
---|---|
US (2) | US5521213A (de) |
EP (1) | EP0778834B1 (de) |
JP (1) | JPH10504829A (de) |
AT (1) | ATE189218T1 (de) |
AU (1) | AU689302B2 (de) |
CA (1) | CA2197895A1 (de) |
DE (1) | DE69514813T2 (de) |
DK (1) | DK0778834T3 (de) |
ES (1) | ES2144623T3 (de) |
GR (1) | GR3033127T3 (de) |
PT (1) | PT778834E (de) |
WO (1) | WO1996006840A1 (de) |
Families Citing this family (199)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515014B2 (en) | 1995-06-02 | 2003-02-04 | G. D. Searle & Co. | Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
US5567828A (en) * | 1995-06-07 | 1996-10-22 | Eli Lilly And Company | Compounds and compositions with nitrogen-containing non-basic side |
WO1996041645A1 (en) | 1995-06-12 | 1996-12-27 | G.D. Searle & Co. | Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations |
US5700816A (en) * | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
PT880362E (pt) | 1996-02-13 | 2005-10-31 | Searle & Co | Composicoes compreendendo um inibidor do cicloxigenase tipo 2 e um antagonista do receptor do leucotrieno b4 |
US5908858A (en) | 1996-04-05 | 1999-06-01 | Sankyo Company, Limited | 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses |
FR2751966B1 (fr) * | 1996-08-01 | 1998-10-30 | Union Pharma Scient Appl | Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique |
TWI235060B (en) | 1996-10-15 | 2005-07-01 | Searle & Co | Pharmaceutical compositions comprising substituted pyrazolyl benzenesulfonamide derivatives for use in treating or preventing an epithelial cell-derived neoplasia |
ES2215242T3 (es) * | 1996-11-19 | 2004-10-01 | Amgen Inc. | Agentes antiinflamatorios de pirrol condensado sustituido con arilo y heteroarilo. |
TR199901703T2 (xx) * | 1996-11-19 | 2000-07-21 | G.D. Searle & Co. | Siklooksijenaz-2 inhibit�rlerini anti-anjiyojenik ajanlar olarak kullanma y�ntemi. |
WO1998037235A1 (en) | 1997-02-24 | 1998-08-27 | Cornell Research Foundation, Inc. | Method of screening agents as candidates for drugs or sources of drugs |
ATE271547T1 (de) * | 1997-03-14 | 2004-08-15 | Merck Frosst Canada Inc | Pyridazinone als inhibitoren von cyclooxygenase-2 |
US6004960A (en) * | 1997-03-14 | 1999-12-21 | Merck Frosst Canada, Inc. | Pyridazinones as inhibitors of cyclooxygenase-2 |
WO1998050075A1 (en) * | 1997-05-07 | 1998-11-12 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with nmda-blockers for treating pain |
US6013674A (en) * | 1997-06-02 | 2000-01-11 | Eli Lilly And Company | Cell adhesion inhibitors |
ES2231757T3 (es) * | 1997-09-05 | 2005-05-16 | Glaxo Group Limited | Composiciones farmaceutica que comprenden derivados de 2,3-diaril-pirazolo (1,5-b) piridazina. |
RS49982B (sr) * | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
CN1279682A (zh) | 1997-10-20 | 2001-01-10 | 霍夫曼-拉罗奇有限公司 | 双环激酶抑制剂 |
FR2770131A1 (fr) * | 1997-10-27 | 1999-04-30 | Union Pharma Scient Appl | Nouvelle association pharmaceutique a activite analgesique |
FR2771005B1 (fr) * | 1997-11-18 | 2002-06-07 | Union Pharma Scient Appl | Nouvelle association pharmaceutique a activite analgesique |
US6025353A (en) * | 1997-11-19 | 2000-02-15 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents |
US7041694B1 (en) | 1997-12-17 | 2006-05-09 | Cornell Research Foundation, Inc. | Cyclooxygenase-2 inhibition |
HUP0100310A3 (en) * | 1997-12-22 | 2002-11-28 | Euro Celtique Sa | A method of preventing abuse of opioid dosage forms |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
CA2314893C (en) | 1997-12-22 | 2005-09-13 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
GB9804886D0 (en) * | 1998-03-06 | 1998-04-29 | Merck Sharp & Dohme | Therapeutic combination |
WO1999051587A1 (fr) * | 1998-04-01 | 1999-10-14 | Ono Pharmaceutical Co., Ltd. | Derives de thiophene condenses et medicaments contenant ceux-ci comme principe actif |
ATE482945T1 (de) | 1998-05-26 | 2010-10-15 | Chugai Pharmaceutical Co Ltd | Heterozyklische indolderivate und mono- oder diazaindol-derivate |
KR100295206B1 (ko) * | 1998-08-22 | 2001-07-12 | 서경배 | 디아릴벤조피란유도체및이를함유하는시클로옥시게네이즈-2저해제조성물 |
TW587079B (en) * | 1998-09-25 | 2004-05-11 | Almirall Prodesfarma Ag | 2-phenylpyran-4-one derivatives |
JP3420751B2 (ja) * | 1998-11-03 | 2003-06-30 | グラクソ グループ リミテッド | 選択的cox‐2インヒビターとしてのピラゾロピリジン誘導体 |
CA2351224A1 (en) * | 1998-11-12 | 2000-05-25 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with nmda-blockers for treating pain |
US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US6649645B1 (en) | 1998-12-23 | 2003-11-18 | Pharmacia Corporation | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
ATE261444T1 (de) | 1999-02-27 | 2004-03-15 | Glaxo Group Ltd | Pyrazolopyridine |
AU3885901A (en) * | 1999-09-21 | 2001-04-24 | Emory University | Methods and compositions for treating platelet-related disorders |
KR100793668B1 (ko) * | 1999-12-08 | 2008-01-10 | 파마시아 코포레이션 | 강화된 생체이용률을 지닌 고체상 형태의 셀레콕시브 |
GB9930358D0 (en) | 1999-12-22 | 2000-02-09 | Glaxo Group Ltd | Process for the preparation of chemical compounds |
EP1263759B1 (de) | 1999-12-24 | 2010-09-08 | Aventis Pharma Limited | Azaindole |
DE60135441D1 (de) | 2000-02-08 | 2008-10-02 | Euro Celtique Sa | Zusammensetzungen mit kontrollierter freisetzung, die einen opioid agonist und antagonist enthalten |
EP1299104B1 (de) | 2000-02-08 | 2009-05-13 | Euro-Celtique S.A. | Missbrauchssichere orale opioid-agonist zubereitungen |
PE20011333A1 (es) | 2000-03-16 | 2002-01-16 | Almirall Prodesfarma Ag | Derivados de 2-fenilpiran-4-ona como inhibidores de ciclooxigenasa 2 |
WO2001081332A2 (en) | 2000-04-25 | 2001-11-01 | Pharmacia Corporation | 2-fluorobenzenesulfonyl compounds for the treatment of inflammation |
WO2001087880A1 (fr) * | 2000-05-15 | 2001-11-22 | Grelan Pharmaceutical Co., Ltd. | Derives de 1-(benzathiazol-2-yl)pyrazole et inhibiteurs de cox-2 en contenant |
WO2002005848A2 (en) * | 2000-07-13 | 2002-01-24 | Pharmacia Corporation | Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders |
PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
PT1303265E (pt) | 2000-07-20 | 2007-10-09 | Lauras As | ''utilização de inibidores da cox-2 como imuno-estimulantes, no tratamento do vih ou da sida'' |
US6716829B2 (en) | 2000-07-27 | 2004-04-06 | Pharmacia Corporation | Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders |
PE20020506A1 (es) * | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
PT1347963E (pt) * | 2000-12-05 | 2004-12-31 | Hoffmann La Roche | Derivados de benzofurano e de benzotiofeno como inibidores selectivos da cox-2 |
US6919352B2 (en) | 2000-12-15 | 2005-07-19 | Smithkline Beecham Corporation | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds |
DE60112330T2 (de) | 2000-12-15 | 2006-04-13 | Glaxo Group Ltd., Greenford | Pyrazolopyridinderivate |
US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
US7153855B2 (en) | 2001-03-08 | 2006-12-26 | Smithkline Beecham Corporation | Pyrazolopyridinyl pyrimidine therapeutic compounds |
US7034030B2 (en) | 2001-03-30 | 2006-04-25 | Smithkline Beecham Corporation | Pyralopyridines, process for their preparation and use as therapeutic compounds |
US7695736B2 (en) | 2001-04-03 | 2010-04-13 | Pfizer Inc. | Reconstitutable parenteral composition |
WO2002083672A1 (en) | 2001-04-10 | 2002-10-24 | Smithkline Beecham Corporation | Antiviral pyrazolopyridine compounds |
ES2242028T3 (es) | 2001-04-27 | 2005-11-01 | Smithkline Beecham Corporation | Derivados de pirazolo(1,5-a)piridina. |
US6756498B2 (en) | 2001-04-27 | 2004-06-29 | Smithkline Beecham Corporation | Process for the preparation of chemical compounds |
UA81224C2 (uk) | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
DE60238756D1 (de) | 2001-05-11 | 2011-02-10 | Endo Pharmaceuticals Inc | Opioid enthaltende arzneiform gegen missbrauch |
TWI224101B (en) | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
WO2003000253A1 (en) | 2001-06-20 | 2003-01-03 | Wyeth | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
CN1518550A (zh) | 2001-06-21 | 2004-08-04 | ʷ��˿�������ȳ�ķ����˾ | 用于预防和治疗疱疹病毒感染的咪唑并[1,2-a]吡啶衍生物 |
GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
CA2454328C (en) * | 2001-07-18 | 2008-03-18 | Christopher D. Breder | Pharmaceutical combinations of oxycodone and naloxone |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
WO2003013433A2 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Sequestered antagonist formulations |
UA80682C2 (en) * | 2001-08-06 | 2007-10-25 | Pharmacia Corp | Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition |
CA2457361C (en) | 2001-08-06 | 2008-11-04 | Christopher Breder | Opioid agonist formulations with releasable and sequestered antagonist |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
AR038957A1 (es) | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
JP2005508955A (ja) | 2001-10-05 | 2005-04-07 | スミスクライン ビーチャム コーポレーション | ヘルペスウイルス感染の治療で使用されるためのイミダゾ−ピリジン誘導体 |
GB0124934D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124938D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124936D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124941D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124933D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124939D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124932D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
WO2003050120A1 (en) | 2001-12-11 | 2003-06-19 | Smithkline Beecham Corporation | Pyrazolo-pyridine derivatives as antiherpes agents |
WO2003055873A1 (en) | 2001-12-21 | 2003-07-10 | H. Lundbeck A/S | Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors |
US20030212138A1 (en) * | 2002-01-14 | 2003-11-13 | Pharmacia Corporation | Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
US20030220374A1 (en) * | 2002-01-14 | 2003-11-27 | Pharmacia Corporation | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors |
US6653346B1 (en) * | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
US7078541B2 (en) * | 2002-02-07 | 2006-07-18 | Galileo Pharmaceuticals, Inc. | Benzofuran derivatives |
EP1474395B1 (de) * | 2002-02-12 | 2007-10-17 | Smithkline Beecham Corporation | Nicotinamide und deren verwendung als p38 inhibitoren |
EP2425821B1 (de) | 2002-04-05 | 2017-05-10 | Euro-Celtique S.A. | Pharmazeutische Zubereitung mit Oxycodon und Naloxon |
AU2003230965B2 (en) | 2002-04-17 | 2008-02-21 | The Cleveland Clinic Foundation | Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents |
ES2375181T3 (es) | 2002-05-09 | 2012-02-27 | The Brigham And Women's Hospital, Inc. | 1l 1rl-1 como un marcador de enfermedades cardiovasculares. |
GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
US6960611B2 (en) * | 2002-09-16 | 2005-11-01 | Institute Of Materia Medica | Sulfonyl-containing 2,3-diarylindole compounds, methods for making same, and methods of use thereof |
EP2422773A3 (de) | 2002-09-20 | 2012-04-18 | Alpharma, Inc. | Sequestriermitteluntereinheit und zugehörige Zusammensetzungen und Verfahren |
JP2006504728A (ja) | 2002-10-03 | 2006-02-09 | スミスクライン ビーチャム コーポレーション | ピラソロピリジン誘導体系治療用化合物 |
US7255860B2 (en) | 2002-10-08 | 2007-08-14 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody |
DE60335957D1 (de) * | 2002-10-08 | 2011-03-17 | Rinat Neuroscience Corp | Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen |
WO2004052853A2 (en) | 2002-12-10 | 2004-06-24 | Wyeth | Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
MXPA05006287A (es) | 2002-12-10 | 2005-09-08 | Wyeth Corp | Derivados de acido indoloxo-acetilaminoacetico sustituidos como inhibidores del inhibidor del activador de plasminogeno 1 (pai-1). |
CN1726190A (zh) | 2002-12-10 | 2006-01-25 | 惠氏公司 | 作为纤溶酶原激活物抑制剂-1(pai-1)的抑制剂的取代3-羰基-1h-吲哚-1-基乙酸衍生物 |
UA80453C2 (en) | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
CA2509191A1 (en) | 2002-12-10 | 2004-06-24 | Wyeth | Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
CA2509605C (en) | 2002-12-13 | 2010-10-05 | Warner-Lambert Company Llc | Alpha-2-delta ligand to treat lower urinary tract symptoms |
US7569364B2 (en) * | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
CA2921578C (en) * | 2002-12-24 | 2017-02-14 | Rinat Neuroscience Corp. | Anti-ngf antibodies and methods using same |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP1594441B1 (de) | 2003-02-19 | 2010-12-15 | Rinat Neuroscience Corp. | Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung |
US20040220155A1 (en) * | 2003-03-28 | 2004-11-04 | Pharmacia Corporation | Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith |
GB0308186D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308201D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
MY135852A (en) | 2003-04-21 | 2008-07-31 | Euro Celtique Sa | Pharmaceutical products |
WO2005009342A2 (en) * | 2003-07-16 | 2005-02-03 | Pharmacia Corporation | Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith |
GB0318814D0 (en) * | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
US20050119262A1 (en) * | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
EP3081214A3 (de) | 2003-08-29 | 2016-11-16 | The Brigham And Women's Hospital, Inc. | Zellnekrosehemmer |
WO2005023189A2 (en) * | 2003-09-03 | 2005-03-17 | Pharmacia Corporation | Method of cox-2 selective inhibitor and nitric oxide-donating agent |
US7442805B2 (en) | 2003-09-25 | 2008-10-28 | Wyeth | Substituted sulfonamide-indoles |
US7265148B2 (en) | 2003-09-25 | 2007-09-04 | Wyeth | Substituted pyrrole-indoles |
US7420083B2 (en) | 2003-09-25 | 2008-09-02 | Wyeth | Substituted aryloximes |
US7141592B2 (en) | 2003-09-25 | 2006-11-28 | Wyeth | Substituted oxadiazolidinediones |
US7268159B2 (en) | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
US7342039B2 (en) | 2003-09-25 | 2008-03-11 | Wyeth | Substituted indole oximes |
PL1663229T3 (pl) | 2003-09-25 | 2010-09-30 | Euro Celtique Sa | Farmaceutyczne kombinacje hydrokodonu i naltreksonu |
US7446201B2 (en) | 2003-09-25 | 2008-11-04 | Wyeth | Substituted heteroaryl benzofuran acids |
US7332521B2 (en) | 2003-09-25 | 2008-02-19 | Wyeth | Substituted indoles |
US7411083B2 (en) | 2003-09-25 | 2008-08-12 | Wyeth | Substituted acetic acid derivatives |
US7534894B2 (en) | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
US7582773B2 (en) | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
US7163954B2 (en) | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
US7351726B2 (en) | 2003-09-25 | 2008-04-01 | Wyeth | Substituted oxadiazolidinediones |
WO2005044227A1 (en) * | 2003-11-05 | 2005-05-19 | Glenmark Pharmaceuticals Limited | Topical pharmaceutical compositions |
US20050100594A1 (en) * | 2003-11-12 | 2005-05-12 | Nilendu Sen | Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor |
US7067159B2 (en) | 2003-12-05 | 2006-06-27 | New Chapter, Inc. | Methods for treating prostate cancer with herbal compositions |
ATE546734T1 (de) | 2003-12-05 | 2012-03-15 | Cleveland Clinic Foundation | Risikomarker für eine herzkreislaufkrankheit |
US7070816B2 (en) | 2003-12-05 | 2006-07-04 | New Chapter, Inc. | Methods for treating prostatic intraepithelial neoplasia with herbal compositions |
AU2004298486A1 (en) | 2003-12-12 | 2005-06-30 | Wyeth | Quinolines useful in treating cardiovascular disease |
EP1708718A1 (de) | 2004-01-22 | 2006-10-11 | Pfizer Limited | Triazol-derivate zur hemmung der vasopressing-antagonistischen aktivität |
GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
KR20060135060A (ko) | 2004-04-07 | 2006-12-28 | 리나트 뉴로사이언스 코퍼레이션 | 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법 |
JP2007534740A (ja) * | 2004-04-28 | 2007-11-29 | ファイザー・インク | バソプレッシンV1a受容体の阻害剤としての3−ヘテロシクリル−4−フェニル−トリアゾール誘導体 |
EP1604666A1 (de) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit |
DK1765292T3 (en) | 2004-06-12 | 2018-01-02 | Collegium Pharmaceutical Inc | ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS |
RU2007106868A (ru) | 2004-08-23 | 2008-09-27 | Вайет (Us) | Оксазол-нафтиловые кислоты и их применение в качестве модуляторов ингибитора активатора плазминогена-1 (pai) для лечения тромбоза и сердечно-сосудистых заболеваний |
CN101044127A (zh) | 2004-08-23 | 2007-09-26 | 惠氏公司 | 用作纤溶酶原激活剂抑制剂-1的噻唑基-萘基酸 |
BRPI0514549A (pt) | 2004-08-23 | 2008-06-17 | Wyeth Corp | ácidos de pirrol-naftila como inibidores de pai-1 |
US7622142B2 (en) | 2004-09-14 | 2009-11-24 | New Chapter Inc. | Methods for treating glioblastoma with herbal compositions |
WO2006041855A2 (en) | 2004-10-04 | 2006-04-20 | Nitromed, Inc. | Compositions and methods using apocynin compounds and nitric oxide donors |
US20080051416A1 (en) * | 2004-10-05 | 2008-02-28 | Smithkline Beecham Corporation | Novel Compounds |
WO2006042192A2 (en) | 2004-10-06 | 2006-04-20 | The Brigham And Womens's Hospital, Inc. | Relevance of achieved levels of markers of systemic inflammation following treatment |
SI2213652T1 (sl) * | 2004-12-17 | 2015-03-31 | The Trustees Of The University Of Pennsylvania | Derivati stilbena in njihova uporaba za vezavo in prikaz amiloidnih plakov |
US7858072B2 (en) * | 2004-12-17 | 2010-12-28 | The Trustees Of The University Of Pennsylvania | Stilbene derivatives and their use for binding and imaging amyloid plaques |
US20060183758A1 (en) * | 2005-02-17 | 2006-08-17 | Cb Research And Development, Inc. | Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans |
EP1702558A1 (de) * | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Verfahren und Vorrichtung zur Darmtätigkeitserfassung |
GB0512429D0 (en) * | 2005-06-17 | 2005-07-27 | Smithkline Beecham Corp | Novel compound |
EP1915157A4 (de) | 2005-08-02 | 2010-09-01 | Nicox Sa | Stickoxidverstärkende antimikrobielle verbindungen, zusammensetzungen und verwendungsverfahren |
EP1919866A2 (de) | 2005-08-17 | 2008-05-14 | Wyeth a Corporation of the State of Delaware | Substituierte indole und deren verwendung |
US8119358B2 (en) * | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
EP1954685A4 (de) | 2005-11-16 | 2009-11-11 | Nitromed Inc | Furoxanverbindungen, zusammensetzungen und anwendungsverfahren |
HUE056086T2 (hu) | 2006-03-15 | 2022-01-28 | Brigham & Womens Hospital Inc | Gelszolin alkalmazása gyulladásos betegségek diagnosztizálására és kezelésére |
EP2007705A4 (de) | 2006-03-29 | 2011-09-07 | Nicox Sa | Stickstoffmonoxid verstärkende prostaglandinverbindungen, zusammensetzung und anwendungsverfahren |
EP2030025A2 (de) | 2006-06-07 | 2009-03-04 | Tethys Bioscience, Inc. | Mit arteriovaskulären ereignissen assoziierte marker und verfahren zu ihrer verwendung |
KR20140079441A (ko) | 2006-06-19 | 2014-06-26 | 알파마 파머슈티컬스 엘엘씨 | 약제학적 조성물 |
TW200819426A (en) | 2006-08-31 | 2008-05-01 | Lundbeck & Co As H | Novel indane compounds |
EA017171B1 (ru) | 2006-12-22 | 2012-10-30 | Рекордати Айерленд Лимитед | КОМБИНИРОВАННАЯ ТЕРАПИЯ ЗАБОЛЕВАНИЙ НИЖНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ С ИСПОЛЬЗОВАНИЕМ ЛИГАНДОВ αδ И НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ (НПВП) |
CA2676413A1 (en) * | 2007-01-19 | 2008-07-31 | Mallinckrodt Inc. | Diagnostic and therapeutic cyclooxygenase-2 binding ligands |
ES2434215T3 (es) | 2007-04-18 | 2013-12-16 | Tethys Bioscience, Inc. | Biomarcadores relacionados con la diabetes y métodos de uso de los mismos |
BRPI0814542A2 (pt) | 2007-07-12 | 2014-09-30 | Tragara Pharmaceuticals Inc | Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores |
US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
GB2462022B (en) | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof |
WO2010003963A1 (en) * | 2008-07-07 | 2010-01-14 | Euro-Celtique S.A. | Use of opioid antagonists for treating urinary retention |
WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
US20100160351A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
JP5596364B2 (ja) * | 2009-02-19 | 2014-09-24 | 住友化学株式会社 | 含窒素有機化合物及びそれを用いた有機エレクトロルミネッセンス素子 |
JP5886632B2 (ja) | 2009-03-10 | 2016-03-16 | ユーロ−セルティーク エス.エイ. | オキシコドンおよびナロキソンを含む即時放出医薬組成物 |
WO2011032175A1 (en) | 2009-09-14 | 2011-03-17 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
CN103037829A (zh) | 2010-02-01 | 2013-04-10 | 儿童医院 | 用于治疗和预防再狭窄的远程缺血调节 |
CA2795053A1 (en) | 2010-03-31 | 2011-10-06 | The Hospital For Sick Children | Use of remote ischemic conditioning to improve outcome after myocardial infarction |
AU2011291462A1 (en) | 2010-08-19 | 2013-03-14 | Zoetis Belgium S.A. | Anti-NGF antibodies and their use |
PL2826467T3 (pl) | 2010-12-22 | 2018-01-31 | Purdue Pharma Lp | Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu |
ES2581323T3 (es) | 2010-12-23 | 2016-09-05 | Purdue Pharma Lp | Formas de dosificación oral sólida resistentes a alteraciones |
HUE044062T2 (hu) | 2011-05-20 | 2019-09-30 | Alderbio Holdings Llc | Anti-CGRP készítmények és alkalmazásuk |
CA2873214C (en) | 2012-05-11 | 2021-02-16 | Reset Therapeutics, Inc. | Carbazole-containing sulfonamides as cryptochrome modulators |
AP2015008579A0 (en) | 2013-02-05 | 2015-07-31 | Purdue Pharma Lp | Tamper resistant pharmaceutical formulations |
US9725452B2 (en) | 2013-03-15 | 2017-08-08 | Presidents And Fellows Of Harvard College | Substituted indoles and pyrroles as RIP kinase inhibitors |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
KR20160034352A (ko) | 2013-07-23 | 2016-03-29 | 유로-셀티큐 에스.에이. | 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물 |
TWI690521B (zh) | 2014-04-07 | 2020-04-11 | 美商同步製藥公司 | 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類 |
EP3292213A1 (de) | 2015-05-04 | 2018-03-14 | Academisch Medisch Centrum | Biomarker für den nachweis von aspirinunempfindlichkeit |
KR102444717B1 (ko) | 2016-04-15 | 2022-09-16 | 하. 룬드벡 아크티에셀스카브 | 인간화 항-pacap 항체 및 그의 용도 |
US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
EP3852732A1 (de) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Peg-lipide und deren verwendung |
WO2020061295A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
CA3209491A1 (en) | 2021-03-15 | 2022-09-22 | Saul Yedgar | Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease |
CA3229059A1 (en) | 2021-08-27 | 2023-03-02 | H. Lundbeck A/S | Treatment of cluster headache using anti-cgrp antibodies |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4477463A (en) * | 1982-05-10 | 1984-10-16 | E. I. Du Pont De Nemours And Company | Antiinflammatory and/or analgesic 1-alkyl-4,5-diaryl-2-fluoroalkyl-1H-pyrroles |
US4652582A (en) * | 1985-01-09 | 1987-03-24 | E. I. Du Pont De Nemours And Company | Antiinflammatory-2-halo-4,5-diarylpyrroles |
US4767766A (en) * | 1987-01-30 | 1988-08-30 | Merck & Co., Inc. | Derivatives of 3-hydroxyazabenzo(B)thiophene useful as 5-lipoxygenase inhibitors |
ATE160345T1 (de) * | 1993-01-15 | 1997-12-15 | Searle & Co | 3,4-diarylthiophene und analoga davon, sowie deren verwendung als entzündungshemmende mittel |
AU6718494A (en) * | 1993-05-13 | 1994-12-12 | Merck Frosst Canada Inc. | 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase |
-
1994
- 1994-08-29 US US08/297,461 patent/US5521213A/en not_active Expired - Fee Related
-
1995
- 1995-08-24 JP JP8508373A patent/JPH10504829A/ja not_active Ceased
- 1995-08-24 AU AU32492/95A patent/AU689302B2/en not_active Ceased
- 1995-08-24 PT PT95928912T patent/PT778834E/pt unknown
- 1995-08-24 ES ES95928912T patent/ES2144623T3/es not_active Expired - Lifetime
- 1995-08-24 AT AT95928912T patent/ATE189218T1/de not_active IP Right Cessation
- 1995-08-24 WO PCT/CA1995/000490 patent/WO1996006840A1/en active IP Right Grant
- 1995-08-24 EP EP95928912A patent/EP0778834B1/de not_active Expired - Lifetime
- 1995-08-24 CA CA002197895A patent/CA2197895A1/en not_active Abandoned
- 1995-08-24 DE DE69514813T patent/DE69514813T2/de not_active Expired - Fee Related
- 1995-08-24 DK DK95928912T patent/DK0778834T3/da active
- 1995-08-24 US US08/793,931 patent/US6329421B1/en not_active Expired - Fee Related
-
2000
- 2000-03-31 GR GR20000400818T patent/GR3033127T3/el not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
See references of WO9606840A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU689302B2 (en) | 1998-03-26 |
DE69514813T2 (de) | 2000-08-17 |
DK0778834T3 (da) | 2000-04-17 |
GR3033127T3 (en) | 2000-08-31 |
EP0778834B1 (de) | 2000-01-26 |
WO1996006840A1 (en) | 1996-03-07 |
JPH10504829A (ja) | 1998-05-12 |
DE69514813D1 (en) | 2000-03-02 |
PT778834E (pt) | 2000-06-30 |
AU3249295A (en) | 1996-03-22 |
US6329421B1 (en) | 2001-12-11 |
CA2197895A1 (en) | 1996-03-07 |
ATE189218T1 (de) | 2000-02-15 |
ES2144623T3 (es) | 2000-06-16 |
US5521213A (en) | 1996-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU689302B2 (en) | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 | |
US6239173B1 (en) | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor | |
EP0828724B1 (de) | Diaryl-5-oxygenierte-2-(5h)-furanone als cox-2-inhibitoren | |
EP0799218B1 (de) | Diaryl-2(5h)-fuaranone als cox-2-inhibitoren | |
US6222048B1 (en) | Diaryl-2-(5H)-furanones as Cox-2 inhibitors | |
WO1994026731A1 (en) | 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase | |
EP0739340A1 (de) | Phenyl-heterocyclen als cox-2 inhibitoren | |
EP0904269B1 (de) | 3,4-diaryl-2-hydroxy-2,5-dihydrofurane als wirkstoffvorstufen von cox-2 inhibitoren | |
US6057319A (en) | 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors | |
EP0889878B1 (de) | Bisarylcyclobutenderivate als cyclooxygenasehemmer | |
US6486194B2 (en) | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases | |
JP3490406B2 (ja) | シクロオキシゲナーゼ−2阻害剤としてのフェニルヘテロ環 | |
AU711902C (en) | 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors | |
CA2244140C (en) | Alkylated styrenes as prodrugs to cox-2 inhibitors | |
AU4529900A (en) | Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970401 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19971111 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MERCK FROSST CANADA & CO. |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
REF | Corresponds to: |
Ref document number: 189218 Country of ref document: AT Date of ref document: 20000215 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM & CO. PATENTANWAELTE Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69514813 Country of ref document: DE Date of ref document: 20000302 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
ITF | It: translation for a ep patent filed |
Owner name: SOCIETA' ITALIANA BREVETTI S.P.A. |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2144623 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20000317 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20030630 Year of fee payment: 9 Ref country code: AT Payment date: 20030630 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20030701 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20030702 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20030704 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20030707 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20030722 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20030729 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20030804 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20030805 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20030818 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20030829 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20030923 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20031006 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040824 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040824 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040824 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040824 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040825 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040825 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040831 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040831 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040831 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050224 |
|
BERE | Be: lapsed |
Owner name: *MERCK FROSST CANADA & CO. Effective date: 20040831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050301 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050303 |
|
EUG | Se: european patent has lapsed | ||
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20040824 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050429 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20050224 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20050301 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050824 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20040825 |
|
BERE | Be: lapsed |
Owner name: *MERCK FROSST CANADA & CO. Effective date: 20040831 |